Xue, B., Liu, Y., Zhang, M., Xiao, G., Luo, X., Zhou, L., . . . Hao, X. (2025). An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk. Chinese Medical Journal, 138(1), 108-110. https://doi.org/10.1097/CM9.0000000000003343
Chicago-referens (17:e uppl.)Xue, Bin, et al. "An Assessment Model for Efficacy of Autologous CD19 Chimeric Antigen Receptor T-cell Therapy and Relapse or Refractory Diffuse Large B-cell Lymphoma Risk." Chinese Medical Journal 138, no. 1 (2025): 108-110. https://doi.org/10.1097/CM9.0000000000003343.
MLA-referens (9:e uppl.)Xue, Bin, et al. "An Assessment Model for Efficacy of Autologous CD19 Chimeric Antigen Receptor T-cell Therapy and Relapse or Refractory Diffuse Large B-cell Lymphoma Risk." Chinese Medical Journal, vol. 138, no. 1, 2025, pp. 108-110, https://doi.org/10.1097/CM9.0000000000003343.
